1997
DOI: 10.1016/s1011-1344(96)00005-x
|View full text |Cite
|
Sign up to set email alerts
|

In vivo photodynamic therapy with the new near-IR absorbing water soluble photosensitizer lutetium texaphyrin and a high intensity pulsed light delivery system

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
17
0
1

Year Published

1998
1998
2016
2016

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 30 publications
(21 citation statements)
references
References 14 publications
3
17
0
1
Order By: Relevance
“…The present study is limited to four compounds: sulfonated chloro-aluminum phthalocyanine (AlPcS n ) [14], benzoporphyrin derivative monoacid ring A (BPD-MA) [15,16], lutetium texaphyrin (Lutex) [17][18][19], and aminolevulinic acid (ALA), a precursor of the endogenous sensitizer protoporphyrin IX (PpIX) [20]. In Table 1 Thursday we present some published results of the PDT efficiency, relative to Photofrin, of these selected sensitizers [21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38].…”
Section: Introductionmentioning
confidence: 99%
“…The present study is limited to four compounds: sulfonated chloro-aluminum phthalocyanine (AlPcS n ) [14], benzoporphyrin derivative monoacid ring A (BPD-MA) [15,16], lutetium texaphyrin (Lutex) [17][18][19], and aminolevulinic acid (ALA), a precursor of the endogenous sensitizer protoporphyrin IX (PpIX) [20]. In Table 1 Thursday we present some published results of the PDT efficiency, relative to Photofrin, of these selected sensitizers [21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38].…”
Section: Introductionmentioning
confidence: 99%
“…Aside from diagnostic usage, porphyrin derivatives have also been developed as an agent for photodynamic therapy (CalzavaraPinton et al, 1996;Hill et al, 1996;Kessel, 1992;Kostenich et al, 1997;Lapes et al, 1996;McIlroy et al, 1998;Nakajima et al, 1998;Shopova et al, 1994;Takemura et al, 1992;Woodburn et al, 1998), radiation sensitizer (Rowinsky 1999;Viala et al, 1999) and an agent for neutron capture therapy (Matsumura et al, 1999;Miura et al, 1996;Shibata et al, 1998). This study revealed that the enhancement effect of the tumour demonstrated on the MR images was well correlated with the biodistribution of the HOP-9P (Figure 2, Table 1).…”
Section: Discussionmentioning
confidence: 99%
“…Besides their usage in various imaging platforms, some of the NIR imaging agents are also used as a PS in PDT applications (32)(33)(34)(35). PDT is a promising non-invasive localized treatment modality for a diverse range of diseases, including various types of cancers, infections, and inflammatory conditions.…”
Section: Therapymentioning
confidence: 99%